Halozyme Therapeutics (HALO) to Release Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALOGet Rating) is set to post its quarterly earnings results after the market closes on Tuesday, November 8th. Analysts expect Halozyme Therapeutics to post earnings of $0.48 per share for the quarter. Halozyme Therapeutics has set its FY 2022 guidance at $2.10-$2.25 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.03. The firm had revenue of $152.37 million for the quarter, compared to the consensus estimate of $156.00 million. Halozyme Therapeutics had a net margin of 75.11% and a return on equity of 101.73%. The business’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 EPS. On average, analysts expect Halozyme Therapeutics to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $46.59 on Friday. The firm’s 50-day moving average price is $42.43 and its 200-day moving average price is $44.07. The company has a quick ratio of 2.23, a current ratio of 2.72 and a debt-to-equity ratio of 3.91. The company has a market cap of $6.42 billion, a PE ratio of 18.42, a PEG ratio of 0.88 and a beta of 1.22. Halozyme Therapeutics has a 52-week low of $31.36 and a 52-week high of $52.98.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors have recently made changes to their positions in HALO. Natixis Advisors L.P. raised its stake in Halozyme Therapeutics by 25.2% during the 2nd quarter. Natixis Advisors L.P. now owns 37,840 shares of the biopharmaceutical company’s stock worth $1,665,000 after acquiring an additional 7,621 shares during the period. LPL Financial LLC raised its stake in Halozyme Therapeutics by 14.1% during the 2nd quarter. LPL Financial LLC now owns 16,497 shares of the biopharmaceutical company’s stock worth $726,000 after acquiring an additional 2,041 shares during the period. PNC Financial Services Group Inc. raised its stake in Halozyme Therapeutics by 31.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 16,826 shares of the biopharmaceutical company’s stock worth $671,000 after acquiring an additional 4,066 shares during the period. United Services Automobile Association bought a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $663,000. Finally, US Bancorp DE raised its stake in Halozyme Therapeutics by 43.8% during the 1st quarter. US Bancorp DE now owns 12,663 shares of the biopharmaceutical company’s stock worth $506,000 after acquiring an additional 3,859 shares during the period. Institutional investors own 91.72% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Morgan Stanley initiated coverage on shares of Halozyme Therapeutics in a report on Friday, September 9th. They set an “overweight” rating and a $50.00 price target on the stock. StockNews.com initiated coverage on shares of Halozyme Therapeutics in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $52.00.

Halozyme Therapeutics Company Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Stories

Earnings History for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.